Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond

被引：3

作者：

De Felice, Francesca ^{[1
]}

Vertechy, Laura ^{[2
]}

Giudice, Elena ^{[2
]}

Ergasti, Raffaella ^{[2
]}

Boccia, Serena ^{[2
]}

Fagotti, Anna ^{[2
,3
]}

Scambia, Giovanni ^{[2
,3
]}

Marchetti, Claudia ^{[2
]}

机构：

[1] Sapienza Univ Rome, Policlin Umberto I, Dept Radiotherapy, Rome, Italy

[2] Fdn Policlin Univ A Gemelli IRCCS, Dept Woman Child & Publ Hlth, Rome, Italy

[3] Univ Cattolica Sacro Cuore, Inst Obstet & Gynecol, Rome, Italy

来源：

JOURNAL OF ONCOLOGY | 2021年 / 2021卷

关键词：

MAINTENANCE THERAPY; DOUBLE-BLIND; OLAPARIB; WOMEN;

D O I：

10.1155/2021/1682532

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose. A practice synthesis of available evidence-based medicine data in ovarian cancer (OC), aiming to provide directions for future research. Materials and Methods. We performed a systematic review. PubMed was searched for relevant OC trials between January 2000 and December 2019. Results. Out of 865 references screened, 199 trials were found eligible for inclusion. Most trials were multicenter (83.9%). There was a trend reduction in the number of patients enrolled/per study over the years. Studies testing targeted/biological therapies dominated the second decade (60 trials in 2010-2019 versus 2 trials in 2000-2009). The proportion of trials with positive survival and clinical outcomes significantly increased from 23.8% in early 2000s to 54.1% in the last 5 years. Trials with histology/molecular biomarker criteria were more likely to meet progression-free survival endpoint than those without these selection criteria (69.2% versus 32.6%). Conclusion. This systematic review suggests a trend of increased positive studies, mainly linked to precision medicine.</p>

引用

页数：5

共 18 条

[1] Evidence-based medicine: What it is and what it is not [J].

Bhandari, M ;

Giannoudis, PV .

INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2006, 37 (04) :302-306

[2] Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].

Coleman, R. L. ;

Fleming, G. F. ;

Brady, M. F. ;

Swisher, E. M. ;

Steffensen, K. D. ;

Friedlander, M. ;

Okamoto, A. ;

Moore, K. N. ;

Ben-Baruch, N. Efrat ;

Werner, T. L. ;

Cloven, N. G. ;

Oaknin, A. ;

DiSilvestro, P. A. ;

Morgan, M. A. ;

Nam, J. -H. ;

Leath, C. A., III ;

Nicum, S. ;

Hagemann, A. R. ;

Littell, R. D. ;

Cella, D. ;

Baron-Hay, S. ;

Garcia-Donas, J. ;

Mizuno, M. ;

Bell-McGuinn, K. ;

Sullivan, D. M. ;

Bach, B. A. ;

Bhattacharya, S. ;

Ratajczak, C. K. ;

Ansell, P. J. ;

Dinh, M. H. ;

Aghajanian, C. ;

Bookman, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415

[3] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Coleman, Robert L. ;

Oza, Amit M. ;

Lorusso, Domenico ;

Aghajanian, Carol ;

Oaknin, Ana ;

Dean, Andrew ;

Colombo, Nicoletta ;

Weberpals, Johanne, I ;

Clamp, Andrew ;

Scambia, Giovanni ;

Leary, Alexandra ;

Holloway, Robert W. ;

Amenedo Gancedo, Margarita ;

Fong, Peter C. ;

Goh, Jeffrey C. ;

O'Malley, David M. ;

Armstrong, Deborah K. ;

Garcia-Donas, Jesus ;

Swisher, Elizabeth M. ;

Floquet, Anne ;

Konecny, Gottfried E. ;

McNeish, lain A. ;

Scott, Clare L. ;

Cameron, Terri ;

Maloney, Lara ;

Isaacson, Jeff ;

Goble, Sandra ;

Grace, Caroline ;

Harding, Thomas C. ;

Raponi, Mitch ;

Sun, James ;

Lin, Kevin K. ;

Giordano, Heidi ;

Ledermann, Jonathan A. .

LANCET, 2017, 390 (10106) :1949-1961

[4] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease [J].

Colombo, N. ;

Sessa, C. ;

du Bois, A. ;

Ledermann, J. ;

McCluggage, W. G. ;

McNeish, I. ;

Morice, P. ;

Pignata, S. ;

Ray-Coquard, I. ;

Vergote, I. ;

Baert, T. ;

Belaroussi, I. ;

Dashora, A. ;

Olbrecht, S. ;

Planchamp, F. ;

Querleu, D. ;

Banerjee, S. ;

Blecharz, P. ;

Bruchim, I. ;

Cibula, D. ;

Concin, N. ;

Davidson, B. ;

Devouassoux-Shisheboran, M. ;

Ferrero, A. ;

Glasspool, R. ;

Gonzalez-Martin, A. ;

Heinzelmann-Schwarz, V. ;

Joly, F. ;

Kim, J. W. ;

Kridelka, F. ;

Lorusso, D. ;

Mahner, S. ;

Mikami, M. ;

Mirza, M. R. ;

Nicum, S. ;

O'Donnell, D. M. ;

Pautier, P. ;

Rodolakis, A. ;

Sehouli, J. ;

Selcukbiricik, F. ;

Singh, N. ;

Tan, D. S. P. ;

Timmerman, D. ;

Tognon, G. ;

van der Velden, J. ;

Witteveen, P. O. ;

Zeimet, A. G. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (04) :728-760

[5] The Changing Landscape of Phase II/III Metastatic NSCLC Clinical Trials and the Importance of Biomarker Selection Criteria [J].

Gentzler, Ryan D. ;

Yentz, Sarah E. ;

Johnson, Melissa L. ;

Rademaker, Alfred W. ;

Patel, Jyoti D. .

CANCER, 2014, 120 (24) :3853-3858

[6] Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Gonzalez-Martin, A. ;

Pothuri, B. ;

Vergote, I. ;

DePont Christensen, R. ;

Graybill, W. ;

Mirza, M. R. ;

McCormick, C. ;

Lorusso, D. ;

Hoskins, P. ;

Freyer, G. ;

Baumann, K. ;

Jardon, K. ;

Redondo, A. ;

Moore, R. G. ;

Vulsteke, C. ;

O'Cearbhaill, R. E. ;

Lund, B. ;

Backes, F. ;

Barretina-Ginesta, P. ;

Haggerty, A. F. ;

Rubio-Perez, M. J. ;

Shahin, M. S. ;

Mangili, G. ;

Bradley, W. H. ;

Bruchim, I. ;

Sun, K. ;

Malinowska, I. A. ;

Li, Y. ;

Gupta, D. ;

Monk, B. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2391-2402

[7] A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms [J].

Harter, Philipp ;

Sehouli, Jalid ;

Lorusso, Domenica ;

Reuss, Alexander ;

Vergote, Ignace ;

Marth, Christian ;

Kim, Jae-Weon ;

Raspagliesi, Francesco ;

Lampe, Bjoern ;

Aletti, Giovanni ;

Meier, Werner ;

Cibula, David ;

Mustea, Alexander ;

Mahner, Sven ;

Runnebaum, Ingo B. ;

Schmalfeldt, Barbara ;

Burges, Alexander ;

Kimmig, Rainer ;

Scambia, Giovanni ;

Greggi, Stefano ;

Hilpert, Felix ;

Hasenburg, Annette ;

Hillemanns, Peter ;

Giorda, Giorgio ;

von Leffern, Ingo ;

Schade-Brittinger, Carmen ;

Wagner, Uwe ;

du Bois, Andreas .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (09) :822-832

[8] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Macpherson, Euan ;

Watkins, Claire ;

Carmichael, James ;

Matulonis, Ursula .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1382-1392

[9] Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study [J].

Liu, Joyce F. ;

Barry, William T. ;

Birrer, Michael ;

Lee, Jung-Min ;

Buckanovich, Ronald J. ;

Fleming, Gini F. ;

Rimel, B. J. ;

Buss, Mary K. ;

Nattam, Sreenivasa ;

Hurteau, Jean ;

Luo, Weixiu ;

Quy, Philippa ;

Whalen, Christin ;

Obermayer, Lisa ;

Lee, Hang ;

Winer, Eric P. ;

Kohn, Elise C. ;

Ivy, S. Percy ;

Matulonis, Ursula A. .

LANCET ONCOLOGY, 2014, 15 (11) :1207-1214

[10] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer [J].

Mirza, M. R. ;

Monk, B. J. ;

Herrstedt, J. ;

Oza, A. M. ;

Mahner, S. ;

Redondo, A. ;

Fabbro, M. ;

Ledermann, J. A. ;

Lorusso, D. ;

Vergote, I. ;

Ben-Baruch, N. E. ;

Marth, C. ;

Madry, R. ;

Christensen, R. D. ;

Berek, J. S. ;

Dorum, A. ;

Tinker, A. V. ;

du Bois, A. ;

Gonzalez-Martin, A. ;

Follana, P. ;

Benigno, B. ;

Rosenberg, P. ;

Gilbert, L. ;

Rimel, B. J. ;

Buscema, J. ;

Balser, J. P. ;

Agarwal, S. ;

Matulonis, U. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22) :2154-2164

← 1 2 →